Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data

Autores: Owonikoko, T. K.; Papadopoulos, K. P.; Gil-Martin, M. ; Moreno, V.; Salama, A. K.; Calvo, E.; Safran, H.; González Martín, Antonio; Aljumaily, R.; Mahadevan, D.; Niu, J. ; Mohan, K. K.; Li, J.; Stankevich, E.; Mathias, M.; Lowy, I.; Fury, M. G. ; Babiker, H. M.